g. Glaxo preliminary motion 7 under 37 CFR § 1.633(c)(4) to have claims 3,
5, and 7 of Glaxo's '403 patent, claims 3-6 of Glaxo's '404 patent, and claim 5 of Glaxo's '405
patent designated as not corresponding to Count 1 (Paper 53).
h. Glaxo preliminary motion 8 under 37 CFR § 1.633(c)(4) to have claims 2,
4, and 6 of Glaxo's '403 patent and claims 3-5 and 7 of Glaxo's '404 patent designated as not
corresponding to Count 1 (Paper 54).
I. Glaxo preliminary motion 9 under 37 CFR § 1.633(c)(4) to have claims 3-
5 and 7 of Glaxo's '405 patent designated as not corresponding to Count 1 (Paper 55).
j. Glaxo preliminary motion 10 under 37 CFR § 1.633(a) for judgment that
the Cabilly claims are unpatentable under 35 USC 112, ¶1, due to lack of an enabling disclosure
(Paper 56).
k. Glaxo preliminary motion 11 under 37 CFR § 1.633(b) for judgment that
there is no interference-in-fact (Paper 57).
l. Glaxo contingent preliminary motion 12 attacking any priority benefit to
be accorded to Cabilly for the filing date of the '457 application as to proposed Count 2
(Paper 58).
m. Glaxo contingent preliminary motion 13 attacking any priority benefit to
be accorded to Cabilly for the filing date of the '419 application as to proposed Count 2
(Paper 59).
n. Glaxo contingent preliminary motion 14 under 37 CFR § 1.637(f) seeking
priority benefit of earlier filed Glaxo applications as to proposed Count 2 (Paper 60).
-8-
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007